Orchard Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Orchard Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-17.9%
Buyback Yield
| Total Shareholder Yield | -17.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ORTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORTX's dividend payments have been increasing.
Dividend Yield vs Market
| Orchard Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ORTX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.5% |
| Industry Average (Biotechs) | 2.5% |
| Analyst forecast (ORTX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ORTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ORTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ORTX has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/24 21:47 |
| End of Day Share Price | 2024/01/24 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orchard Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Duncan | Cantor Fitzgerald & Co. |
| Emma Nealon | Cantor Fitzgerald & Co. |
| Graig Suvannavejh | Goldman Sachs |